Other OTC - Delayed Quote • USD
Sangui Biotech International, Inc. (SGBI)
At close: January 17 at 2:24 PM EST
Key Executives
Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Mr. Thomas Striepe | CEO, President, CFO & Executive Director | 82.62k | -- | 1962 |
Sangui Biotech International, Inc.
- Sector:
- Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
Description
Sangui Biotech International, Inc., through its subsidiaries, engages in the manufacturing and sales of wound treatment and cosmetic products. The company offers artificial oxygen carriers comprising oxygen carrying blood additives and oxygen carrying blood volume substitutes; nano formulations for the regeneration of skin; chitoskin wound pads; Hemospray, a hemoglobin based wound spray; and wound dressing spray under the Granulox brand. Sangui Biotech International, Inc. was incorporated in 1995 and is headquartered in Hamburg, Germany.
Corporate Governance
Sangui Biotech International, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Recent Events
- May 12, 202310-Q: Periodic Financial ReportsSee Full Filing
- Feb 07, 202310-Q: Periodic Financial ReportsSee Full Filing
- Nov 10, 202210-Q: Periodic Financial ReportsSee Full Filing
- Nov 03, 20228-K: Corporate Changes & Voting MattersSee Full Filing
- Sep 28, 202210-K: Periodic Financial ReportsSee Full Filing
Upcoming Events
Upcoming Events Information Not Available